RPTX News and Press, Repare Therapeutics Inc. From 09/07/22

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate at two investor conferences in September. Details for the fir...

Repare Therapeutics press release ( NASDAQ: RPTX ): Q2 GAAP EPS of -$0.91 misses by $0.06 . Revenue of $0.67M (+139.3% Y/Y). For further details see: Repare Therapeutics GAAP EPS of -$0.91 misses by $0.06, revenue of $0.67M

Signed worldwide license and collaboration agreement with Roche for the development and commercialization of camonsertib (also known as RP-3500) Repare received a $125 million upfront payment in July 2022 as part of the collaboration agreement with Roche, and is eligible to re...

ARK Invest’s 13F portfolio value decreased from $23.96B to $16.91B this quarter. Coinbase Global, Roku, Shopify, and Ginkgo Bioworks were increased while decreasing Spotify, Ionis Pharma, Vertex Pharma, and Sea Limited. The top three positions are Tesla, Zoom Video, and Rok...

Repare Therapeutics is working in synthetic lethality, where big pharma has shown interest. They have some early data. While things look good, I will wait for more conclusive data before I jump in. For further details see: Repare Therapeutics: Interesting Gene Editing Co...

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate in a fireside chat at the Goldman Sachs 43rd Annual Global He...

Repare Therapeutics Inc ( NASDAQ: RPTX ), a top clinical-stage precision oncology corporation, announced that it’s executed a collaboration and worldwide license deal with Roche for both the commercialization and development of RP-3500 (also known as camonsertib). This ne...

Repare Therapeutics (NASDAQ:RPTX) is continuing to benefit Thursday from a licensing deal with Roche (OTCQX:RHHBY) announced after the closing bell Wednesday. In afternoon trading, shares are up ~40%. Under the terms, Repare (RPTX) is receiving $125M in upfront payments and up to $1.2 bi...

After the market closed Wednesday, Repare Therapeutics (NASDAQ: RPTX) announced that it had entered into a licensing and collaboration deal with Roche (OTC: RHHBY) for its experimental cancer drug, camonsertib, also known as RP-3500. In the wake of that news, Repare shares s...

Gainers: Immix Biopharma (IMMX) +37%. Bright Green (BGXX) +29%. Repare Therapeutics (RPTX) +29%. Yumanity Therapeutics (YMTX) +24%. PDS Biotechnology (PDSB) +15%. Losers: Zosano Pharma (ZSAN) -48%. Immunic (IMUX) -41%. Aeglea BioTherapeutics (AGLE) -40%...